Phytotherapie gegen die Corona-Pandemie – realisierte Möglichkeiten, verpasste Chancen?^[*]

Zusammenfassung

Im Jahr drei der Pandemie blicken wir auf zahlreiche Veröffentlichungen zu einem möglichen präventiven wie therapeutischen Nutzen der Phytotherapie. Die Mehrzahl beschreibt z.T. sehr hoffnungsvolle präklinische Effekte. Ein klinischer Nutzen lässt sich derzeit nur sehr bedingt ableiten. Auf zu füllende Lücken wird hingewiesen. Der Artikel behandelt bewusst nur solche Pflanzen, die Bestandteil der Phytotherapie in westlichen Ländern sind.

Abstract

At the beginning of the third year of the pandemic, we are overlooking numerous publications on possible preventive and therapeutic benefits of phytotherapy against SARS-CoV 2. Most of the publications describe very promising preclinical effects. Clinical benefits however, have been demonstrated to a very limited extent. The article points to gaps that need to be filled, while dealing deliberately only with plants that are part of phytotherapy in Western countries.

Schlüsselwörter

SARS-CoV-2 - Prävention - Phytotherapie - Review - präklinische Forschung - klinische Studien

Key words

SARS-CoV-2 - prevention - phytotherapy - review - preclinical research - clinical trials

^* geringfügig erweitertes Vortragsmanuskript des Autors anlässlich des 142. ZAEN-Kongresses, Freudenstadt, 26. März 2022

Publication History

Article published online:
04 August 2022

• Literatur

• 1 Hensel A, Spiegler V, Kraft K. Pflanzliche Extrakte gegen virale Infektionen des oberen Rachenraumes. Gibt es rationalisierbare protektive Möglichkeiten?. Z Phytother 2020; 41: 52-54 DOI: 10.1055/a-1102-1662.
• 2 Stange R, Uehleke B. Covid-19: Überlegungen zu Voraussetzungen von phytotherapeutischen Empfehlungen. Z Phytother 2020; 41: 160-164 DOI: 10.1055/a-1102-1740.
• 3 Uehleke B. Arzneipflanzen bei Covid-19. Z Phytother 2020; 41: 291-294 DOI: 10.1055/a-1245-6148.
• 4 Adler M. Retrolektive Therapiebeobachtung im Rahmen der Pandemie mit Covid-19. Z Phytother 2020; 41: 111-112 DOI: 10.1055/a-1102-1686.
• 5 Azimi M, Hasheminasab FS. Evaluating the efficacy and safety of the myrtle (Myrtus communis) in treatment and prognosis of patients suspected to novel coronavirus disease (COVID-19): study protocol for a randomized controlled trial. Trials 2020; 21: 978 DOI: 10.1186/s13063-020-04915-w.
• 6 Koshak AE, Koshak EA, Mobeireek AF. et al. Nigella sativa supplementation to treat symptomatic mild COVID-19: A structured summary of a protocol for a randomised, controlled, clinical trial. Trials 2020; 21: 703 DOI: 10.1186/s13063-020-04647-x.
• 7 Karimi M, Zarei A, Soleymani S. et al. Efficacy of Persian medicine herbal formulations (capsules and decoction) compared to standard care in patients with COVID-19, a multicenter open-labeled, randomized, controlled clinical trial. Phytother Res 2021; 35: 6295-6309 DOI: 10.1002/ptr.7277.
• 8 Internet Archive. https://openlibrary.org/books/OL31211619M/Makhzan_al-adviyah; besucht 11. März 2022
• 9 Sardari S, Mobaien A, Ghassemifard L. et al. Therapeutic effect of thyme (Thymus vulgaris) essential oil on patients with covid19: A randomized clinical trial. J Advances Med Biomed Res 2021; 29: 83-91 DOI: 10.30699/jambs.29.133.83.
• 10 Vahedian-Azimi A, Abbasifard M, Rahimi-Bashar F. et al. Effectiveness of curcumin on outcomes of hospitalized COVID-19 patients: A systematic review of clinical trials. Nutrients 2022; 14: 256 DOI: 10.3390/nu14020256.
• 11 Ahmadi R, Salari S, Sharifi MD. et al. Oral nano-curcumin formulation efficacy in the management of mild to moderate outpatient COVID-19: A randomized triple-blind placebo-controlled clinical trial. Food Sci Nutr 2021; 9: 4068-4075 DOI: 10.1002/fsn3.2226.
• 12 Saber-Moghaddam N, Salari S, Hejazi S. et al. Oral nano-curcumin formulation efficacy in management of mild to moderate hospitalized coronavirus disease-19 patients: An open-label non-randomized clinical trial. Phytother Res 2021; 35: 2616-2623 DOI: 10.1002/ptr.7004.
• 13 Valizadeh H, Abdolmohammadi-Vahid S, Danshina S. et al. Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients. Int Immunopharmacol 2020; 89 (Part B): 107088 DOI: 10.1016/j.intimp.2020.107088.
• 14 Tahmasebi S, El-Esawi MA, Mahmoud ZH. et al. Immunomodulatory effects of nanocurcumin on Th17 cell responses in mild and severe COVID-19 patients. J Cell Physiol 2021; 236: 5325-5338 DOI: 10.1002/jcp.30233.
• 15 Tahmasebi S, Saeed BQ, Temirgalieva E. et al. Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2. Life Sci 2021; 276: 119437 DOI: 10.1016/j.lfs.2021.119437.
• 16 Pawar KS, Mastud RN, Pawar SK. et al. Oral curcumin with piperine as adjuvant therapy for the treatment of COVID-19: A randomized clinical trial. Front Pharmacol 2021; 12: 669362 DOI: 10.3389/fphar.2021.669362.
• 17 Kolev E, Mircheva L, Edwards MR. et al. Echinacea purpurea for the long-term prevention of viral respiratory tract infections during Covid-19 pandemic: A randomized, open, controlled, exploratory clinical study. Front Pharmacol 2022; 13: 856410 DOI: 10.3389/fphar.2022.856410.
• 18 Mukherjee PK, Efferth T, Das B. et al. Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications. Phytomedicine 2022; 98: 153930 DOI: 10.1016/j.phymed.2022.153930.
• 19 Eggers M, Jungke P, Wolkinger V. et al. Antiviral activity of plant juices and green tea against SARS-CoV-2 and influenza virus. Phytother Res 2022; 36: 2109-2115 DOI: 10.1002/ptr.7431.
• 20 Kicker E, Tittel G, Schaller T. et al. SARS-CoV-2 neutralizing activity of polyphenols in a special green tea extract preparation. Phytomedicine 2022; 98: 153970 DOI: 10.1016/j.phymed.2022.153970.
• 21 Papies J, Emanuel J, Heinemann N. et al. Antiviral and immunomodulatory effects of Pelargonium sidoides DC. root extract EPs^® 7630 in SARS-CoV-2-infected human lung cells. Front Pharmacol 2021; 12: 757666 DOI: 10.3389/fphar.2021.757666 Erratum in: Front Pharmacol 2021;12: 814452.
• 22 Mohamed FF, Anhlan D, Schöfbänker M. et al. Hypericum perforatum and its ingredients Hypericin and Pseudohypericin demonstrate an antiviral activity against SARS-CoV-2. Pharmaceuticals (Basel) 2022; 15: 530 DOI: 10.3390/ph15050530.